Our Mission: To revolutionize the diagnostic, prognostic, and predictive treatment of disease by enabling next generation technologies for non-destructively processing and digitally analyzing tissue in 3D. ClearLight Biotechnologies (formerly ClearLight Diagnostics, LLC) was founded in 2015 by Karl Deisseroth MD, PhD, the inventor of CLARITY, Optogenetics, and STARmap technologies. It is an early stage company focused on developing automated instrumentation and associated reagents to simplify and expedite non-destructive 3D tissue analysis to facilitate preclinical and clinical research applications. The platform will enable an end-to-end solution for 3D analysis of preclinical and clinical models of disease. Imagine, Non-destructive tissue processing and digital spatial image analysis in 3D to facilitate your pre-clinical and clinical research studies. Imagine, A way to illuminate your tissue microenvironment in a 3D volume. Imagine, Automating this process and integrating it into your normal tissue processing work flow. The Problem: Current gold standard techniques are 100 years old and rely on the analysis of 2D thin section FFPE (~5-10 micron). Spatial and morphological analysis of the tissue microenvironment is highly limited. 2D is destructive, slide-based, non-digital, is variable, and highly manual and does not represent the entire biology. The Solution: See more biology in 3D. Bringing CLARITY to the complexity of your 3D histopathology models.